Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 3/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2110045 | 0.79 | TLR4 (0.49) | ALDH1A1TSHRTLR4TLR2PDPK1 | |
| SCHEMBL303744 | 0.78 | — | — | |
| SCHEMBL10394210 | 0.78 | — | — | |
| SCHEMBL1680456 | 0.78 | — | — | |
| SCHEMBL10368032 | 0.78 | — | — | |
| SCHEMBL2931895 | 0.76 | TLR4 (0.40) | ALDH1A1TSHRNOS1HSD17B10TLR4 | |
| SCHEMBL4685740 | 0.76 | TLR4 (0.47) | TSHRTLR4TLR2PDPK1ACACB | |
| SCHEMBL4743684 | 0.76 | FBP1 (0.51) | ALDH1A1TSHRFBP1TLR4TLR2 | |
| SCHEMBL3996307 | 0.76 | TLR4 (0.40) | ALDH1A1TSHRNOS1HSD17B10FBP1 | |
| SCHEMBL21274270 | 0.76 | L3MBTL1 (0.44) | ALDH1A1FBP1TLR4TLR2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296922-A1 | POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI WENNAI THERAPEUTICS CO LTD (CN) | 2025-09-25 | — | — | US | claimed |
| WO-2025021115-A1 | POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海闻耐医药科技有限公司 | 2025-01-30 | — | — | WO | claimed |
| US-12612383-B2 | Polysubstituted pyrrolidine derivative, preparation method therefor and use thereof | SHANGHAI WENNAI THERAPEUTICS CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20250296922-A1 | POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI WENNAI THERAPEUTICS CO LTD (CN) | 2025-09-25 | — | — | US | disclosed |
| CN-119790050-A | Oxazole TRPML1 agonists and uses thereof | 利布拉医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119546588-A | Pyridine checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025021115-A1 | POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海闻耐医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-118488945-A | Sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118434417-A | Cyclic sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-116507626-A | Compositions and methods for modulating short-chain dehydrogenase activity | 罗迪奥治疗公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-111509207-A | Porous carbon-coated Co-doped MnO lithium ion battery cathode material and preparation method thereof | 赵东伟 | 2020-08-07 | — | — | CN | disclosed |
| WO-2005123069-A2 | GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| CN-1146575-C | Peptidyl heterocycles useful in the treatment of thrombin related disorders | ��λҩƷ��˾ | 2004-04-21 | — | — | CN | disclosed |
| CN-1192747-A | Peptidyl heterocyclic compounds for the treatment of thrombin-related diseases | ORTHO PHARMA CORP (US) | 1998-09-09 | — | — | CN | disclosed |
| US-4865641-A | Herbicidal new thiazolyl ether and thioether derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-12 | — | — | US | disclosed |
| US-4865641-A | Herbicidal new thiazolyl ether and thioether derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-12 | — | — | US | disclosed |
| EP-0283762-A1 | Thiazolyl ether and thioether derivatives | BAYER AG (DE) | 1988-09-28 | — | — | EP | disclosed |
| EP-0283762-A1 | Thiazolyl ether and thioether derivatives | BAYER AG (DE) | 1988-09-28 | — | — | EP | disclosed |
| EP-0281907-A1 | Thiazolyl ether and thioether derivatives | BAYER AG (DE) | 1988-09-14 | — | — | EP | disclosed |
| EP-0281907-A1 | Thiazolyl ether and thioether derivatives | BAYER AG (DE) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296922-A1 | POLYSUBSTITUTED PYRROLIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SCN8A, SCN11A, TRPV1 | ALDH1A1 2001/4885TSHR 3636/4885NOS1 2100/4885 |
| US-12612383-B2 | Polysubstituted pyrrolidine derivative, preparation method therefor and use thereof | SCN8A, SCN11A, TRPV1 | ALDH1A1 2204/4885TSHR 2586/4885NOS1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.